Arthritis Clinical Trials in Orlando

View 40 new treatments for Arthritis in Orlando, FL, and other areas near me, such as Palm Bay. Every day, Power helps hundreds of arthritis patients connect with leading medical research.
View 36 trials in Orlando
Filter (36)

TG-C for Osteoarthritis of the Knee

Kolon TissueGene Clinic, Viera + 4 more

This trial tests TG-C, an injection into the knee, for patients with moderate to severe osteoarthritis. It aims to reduce pain and improve knee function by potentially modifying the disease. TG-C has shown promise in previous studies for managing knee osteoarthritis.Show More

Verified

Waitlist
Phase 3
Est. 6 - 12 Weeks
Moon Jong Noh, PhD
Study Chair

Baricitinib for Rheumatoid Arthritis

Eli Lilly Clinic, Orlando + 4 more

This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

TG-C for Knee Osteoarthritis

Kolon TissueGene Clinic, DeLand + 2 more

This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
David W Romness, MD
Principal Investigator

Tildrakizumab for Psoriatic Arthritis

Sun Clinic, Kissimmee + 1 more

This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Upadacitinib for Axial Spondyloarthritis

AbbVie Clinic, Winter Park + 1 more

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: * To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2). * To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2). * To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2). * To evaluate the maintenance of disease control after withdrawal of upadacitinib.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
ABBVIE INC.
Study Director

Risankizumab for Psoriatic Arthritis

AbbVie Clinic, Orlando + 2 more

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 6 - 12 Weeks
ABBVIE INC.
Study Director

Tildrakizumab SC Injection for Psoriatic Arthritis

Sun Clinic, Kissimmee + 1 more

An open label phase 3 study
Waitlist

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Risankizumab for Psoriatic Arthritis

AbbVie Clinic, Orlando + 2 more

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
ABBVIE INC.
Study Director

RTX-GRT7039 Injections for Knee Osteoarthritis

GrĂ¼nenthal Clinic, Port Orange + 1 more

This trial uses knee injections called RTX-GRT7039 for patients with knee osteoarthritis who still have pain despite usual treatments. The injections aim to reduce knee pain, possibly by affecting pain pathways or inflammation.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Retatrutide for Obesity

Eli Lilly Clinic, Orlando + 3 more

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
Study Director
Page 1 of 4

Frequently Asked Questions

How much do arthritis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do arthritis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across arthritis trials in Orlando, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for arthritis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

What promising new drugs are being tested?

In Orlando, arthritis research is focusing on treatments like Janus Kinase (JAK) Inhibitors and Monoclonal Antibodies. Notable drugs being studied include Upadacitinib, Risankizumab, and Guselkumab.